Engineering Skin Regeneration
Chronic wounds affect millions of patients worldwide and represent one of the greatest unmet needs in modern healthcare. Diabetic foot ulcers, venous leg ulcers, pressure ulcers and complex surgical wounds often fail to heal despite prolonged treatment, leading to infection, hospitalisation, amputation and substantial healthcare costs.
By combining advanced biomaterial engineering, antibacterial functionality and mechanotransductive technology, we work to restore the biological environment required for effective tissue repair and skin regeneration. Our mission is to transform chronic wound care through innovative, clinically driven solutions that improve patient outcomes and reduce the burden on healthcare systems.
Healing is governed not only by biological signals but also by the mechanical environment surrounding cells. Dermomat's platform harnesses mechanotransduction — the process by which cells convert physical cues into biological responses — to stimulate tissue regeneration and wound repair. Our biomaterials mimic key features of the extracellular matrix while providing structural support, antibacterial protection and regenerative signalling within the wound bed.
An ECM-mimicking architecture presents cells with the structural and mechanical signals of healthy tissue.
Cells sense those cues and convert them into biological activity — attachment, migration and proliferation.
Angiogenesis and remodelling follow, supporting faster closure and better outcomes in hard-to-heal wounds.
Both products share Dermomat's mechanotransductive, antibacterial core. They differ in form, so the right one fits the wound being treated.
Antibacterial mechanotransductive dermal scaffold
A structured scaffold that provides support while actively guiding cell infiltration, vascularisation and tissue remodelling.
Injectable regenerative dermal matrix
A flowable biomaterial that conforms to deep cavities and irregular defects where fixed-form scaffolds are difficult to apply.
We envision a future where chronic wounds are treated through regenerative therapies that restore tissue function rather than simply managing symptoms. Dermomat is committed to developing transformative wound-healing technologies that bridge the gap between laboratory innovation and clinical practice — delivering better outcomes for patients and healthcare providers worldwide.
Speak to our scientists about skin scaffold technology and how to invest in our products.
For clinical, partnership or investment enquiries, send us a message and we'll get back to you.